Choosing Xyosted Over Testosterone Cypionate: Evidence‑Based Considerations

Adherence and Convenience

Patients with limited disease‑management skills or resources benefit from a pre‑filled, single‑dose auto‑injector that eliminates the need to draw medication from vials, reducing complexity and dosing errors. 1
Weekly subcutaneous administration via the auto‑injector is perceived as less intimidating than intramuscular injections, which may improve long‑term adherence. 2

Traditional testosterone cypionate administered every two weeks creates large peaks and troughs that place patients outside the therapeutic range for extended periods, potentially increasing cardiovascular events, hospitalizations, and mortality. 1
Weekly Xyosted dosing yields more stable testosterone concentrations, decreasing the duration spent in supratherapeutic and subtherapeutic ranges compared with bi‑weekly cypionate. 1

Weekly Xyosted maintains mid‑normal testosterone levels (approximately 500–600 ng/dL) with less variability than the peak‑and‑valley pattern seen with bi‑weekly cypionate injections. 1
Because Xyosted provides steadier levels, timing of serum testosterone measurement is less critical than the midpoint‑between‑dose sampling required for cypionate. 1

Traditional testosterone cypionate vials have an estimated annual cost of about $156, making them more cost‑effective than newer auto‑injector systems. 3
When cardiovascular risk or adherence issues are present, cost should not be the primary factor in selecting therapy for patients without financial constraints. 1

Some patients prefer bi‑weekly or monthly injections when they have reliable assistance from healthcare providers or family members, despite the associated hormonal fluctuations. 1
Patients comfortable receiving intramuscular gluteal injections administered by others may not require the convenience of an auto‑injector. 1

Total testosterone should be measured 2–3 months after initiating therapy to achieve target levels of 450–600 ng/dL. 4
Once stable dosing is confirmed, testosterone levels should be re‑checked every 6–12 months. 4
In individuals with recent cardiovascular events, testosterone therapy should be delayed 3–6 months regardless of formulation. 4

Do not assume all injectable testosterone products have equivalent cardiovascular safety; dosing frequency and resulting level fluctuations significantly influence risk. 1
Avoid prescribing bi‑weekly or monthly cypionate to patients with existing cardiovascular disease when weekly Xyosted can provide more stable hormone exposure. 1
Do not overlook adherence barriers (e.g., limited dexterity, visual impairment, poor disease‑management skills) when selecting traditional vial‑and‑syringe systems. 1